At AMP 2025, scientists from Indiana University presented data on a rapid, highly specific PCR assay for histoplasmosis, blastomycosis, and coccidioidomycosis.
The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.